In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates
2021 · Nature · 713 citations
https://doi.org/10.1038/s41586-021-03534-y
T
Taiji Mizoguchi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
40
Papers
2.7K
Citations
19
h-index
23
i10-index
Taiji Mizoguchi is an academic researcher. The author has contributed to research in topics: Atherosclerosis and Cardiovascular Diseases & Gut microbiota and health & T-cell and B-cell Immunology. The author has an h-index of 19, co-authored 34 publications.
Papers by this author
worksCommensal bacteria at the crossroad between cholesterol homeostasis and chronic inflammation in atherosclerosis
2017 · Journal of Lipid Research · 111 citations
https://doi.org/10.1194/jlr.m072165
Intestinal Immunity and Gut Microbiota as Therapeutic Targets for Preventing Atherosclerotic Cardiovascular Diseases
2015 · Circulation Journal · 60 citations
https://doi.org/10.1253/circj.cj-15-0526
† VERVE-102, a clinical stage in vivo base editing medicine, leads to potent and precise inactivation of PCSK9 in preclinical studies
2025 · Journal of clinical lipidology · 5 citations
https://doi.org/10.1016/j.jacl.2025.04.095
Nonclinical data demonstrate potent and precise inactivation of liver PCSK9 in vivo with the clinical stage GalNAc base editing medicine, VERVE-102
2025 · Atherosclerosis · 0 citations
https://doi.org/10.1016/j.atherosclerosis.2025.120333
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat